Trump Touts Pharma Deal That Might Do Something About Drug Prices

April 23, 2026

Another Day, Another Announcement That Sounds Better Than It Actually Is

Thursday morning, President Trump stood in the Oval Office and made a big deal (literally) about a pricing agreement with Regeneron Pharmaceuticals. According to Trump, Regeneron has agreed to reduce the price of drugs sold to Medicaid in some kind of deal that the Trump administration is presenting as a major healthcare victory.

The announcement happened moments after the marijuana reclassification announcement, which is probably not a coincidence. Regeneron is a major pharmaceutical company that would benefit significantly from easier access to marijuana research via the Schedule III reclassification. Suddenly deciding to play nice with Trump on drug pricing right after marijuana gets reclassified? That's suspiciously convenient timing that would never happen in the real world.

Except it's definitely what's happening here.

What the Deal Actually Is (Or Isn't)

The Trump administration hasn't released a lot of details about the Regeneron deal, which is typical of how Trump announcements work. You get a dramatic statement, some applause, and then when people ask for specifics, there's radio silence until the next news cycle.

Based on what's been reported, Regeneron supposedly agreed to reduce prices for drugs sold to Medicaid. That sounds good. Medicaid covers poor people, so reducing prices on Medicaid drugs sounds like it helps poor people afford medication. Which would be genuinely good if it actually works that way.

The reality is usually more complicated. "Reducing prices" to Medicaid could mean a few different things: 1. Actually reducing the prices Medicaid pays (good for Medicaid beneficiaries) 2. Offering rebates that mostly go to insurance companies (good for insurance companies, not really for patients) 3. Reducing prices on a few specific drugs while raising prices on others (neutral to negative overall) 4. Creating a PR victory that looks good but doesn't actually affect many people's costs

Without details, it's impossible to know which of these scenarios we're looking at.

The Marijuana Reclassification Connection

The timing here is too perfect to be accidental. Marijuana gets reclassified to Schedule III Thursday morning. Regeneron suddenly announces a pricing deal hours later. Regeneron is a major pharma company that does research. Schedule III reclassification makes marijuana research dramatically easier. Therefore, Regeneron benefits significantly from the reclassification.

It's not like Regeneron is going to be growing marijuana or selling it. They're a pharmaceutical company that develops drugs derived from active compounds. Easier marijuana research means easier development of cannabis-derived pharmaceuticals, which could be extremely profitable.

So one possible reading of this: Trump's administration reclassifies marijuana (helping the pharmaceutical industry generally, and Regeneron specifically), and in return, Regeneron agrees to do something about Medicaid pricing to give Trump an announcement he can use to claim victory on healthcare.

Is that cynical? Yes. Is it how politics works? Also yes.

What Trump's Healthcare Policy Actually Looks Like in 2026

The Trump administration's healthcare approach is basically: deregulate, let the free market handle it, and occasionally pressure a company into doing something good PR-wise that Trump can then take credit for. The Regeneron deal fits that pattern perfectly.

Instead of a systematic approach to bringing down drug prices across the industry, Trump prefers one-off announcements where individual companies agree to do something, Trump takes a photo op, and then nothing much changes because one company's actions don't affect the broader market.

For actual healthcare policy, you'd want systematic approaches: Medicare allowed to negotiate drug prices (something Trump might actually support now), patent reform to increase generic competition, elimination of middleman profits in the drug supply chain, and actual transparency about why drugs cost what they cost.

What you get instead: announcements about individual companies, mostly so Trump has something positive to say about his administration when people ask about healthcare costs.

The Real Winners and Losers Here

Winners: - Regeneron (gets easier marijuana research capabilities, good publicity for cooperating with Trump) - Trump administration (gets a positive healthcare announcement) - Marijuana research generally (Schedule III reclassification is real) Losers: - Medicaid patients (if this doesn't actually reduce their out-of-pocket costs) - People on other medications (who aren't covered by this deal) - The healthcare system generally (because one company's price reduction doesn't address the structural problems with U.S. drug pricing)

The fact that this deal is being announced as a major victory tells you something about how low the bar has gotten for healthcare policy. One pharmaceutical company agrees to reduce prices on some drugs? That's front page news? That's something the president has to stand in the Oval Office and take credit for?

That's what happens when you don't have an actual healthcare policy. You grab whatever good news you can find and announce it loudly.

Sources: The New York Times (April 23, 2026), White House Statement (April 23, 2026)